CD8A and acute myeloid leukemia: A significant efficiency of anti-PD-1 antibodies (nivolumab) in combination with azacytidine was demonstrated in specific groups of patients with relapsed/refractory AML: HMA-naïve, Salvage 1 and high pre-treatment infiltration of the bone marrow with CD3+ lymphocytes (CD8 predominantly).